Endovascular treatment of long lesions of the superficial femoral artery: Results from a multicenter registry of a spiral, covered polytetrafluoroethylene stent
Endovascular treatment of long lesions of the superficial femoral artery: Results from a multicenter registry of a spiral, covered polytetrafluoroethylene stent
复制标题
DOI：
10.1016/j.jvs.2006.08.032
复制
发表时间：
2007-01-01
影响因子：
4.3
通讯作者：
Cao, Piergiorgio
中科院分区：
文献类型：
--
作者：
Lenti, Massimo;Cieri, Enrico;Cao, Piergiorgio
目的：接受血管内治疗的长股浅动脉（SFA）阻塞患者的结局信息很少。本研究报告了一项旨在评价aSpire自膨式聚四氟乙烯覆膜支架安全性、有效性和通畅性的前瞻性多中心登记研究的结果（Vascular Architects Inc，圣何塞，加利福尼亚州）在股腘动脉闭塞性疾病患者中的应用。aSpire登记研究纳入了150名患者（166条肢体）在28个月期间在16个中心入组（2003 - 2005）中/长（> 3cm）闭塞（n = 115）或狭窄（n = 51）的SFA（n = 51）或近端腘动脉（n = 115）。92例间歇性跛行，33例静息痛，41例肢体疼痛。覆盖的动脉段平均长度为107.35 ± 73.7 mm。根据跨大西洋协会共识分类，治疗适应症包括44例B1型、57例132型、47例C1型和18例D型病变。在出院时和第1、6、12个月以及此后每年进行临床和超声评价。平均随访时间为13个月（范围：1 - 36）。主要终点为即刻技术成功（血管再通伴残余狭窄
Objective: Information on outcome of patients with long superficial femoral artery (SFA) obstruction undergoing endovascular treatment is scarce. The present study reports results from a prospective multicenter registry designed to evaluate the safety, effectiveness, and patency of the aSpire self-expanding polytetrafluoroethylene covered stent (Vascular Architects Inc, San Jose, Calif) in patients with femoropopliteal occlusive disease.Method: The aSpire Registry included 150 patients (166 limbs) enrolled in 16 centers during a 28-month period (2003 to 2005) for medium/long (> 3 cm) occlusion (n = 115) or stenosis (n = 5 1) of the SFA (n = 5 1) or of the proximal popliteal (n = 115) arteries. Procedures were performed for intermittent claudication in 92, for rest pain in 33, and for limb savage in 41. The mean length of arterial segment covered was 107.35 +/- 73.7 mm. Indications for treatment included 44 type B1, 57 type 132, 47 type C1, and 18 type D lesions according to TransAtlantic Inter-Society Consensus classification. Clinical and ultrasound evaluation was per-formed at discharge and at 1, 6, 12 months, and yearly thereafter. Mean follow-up was 13 months (range, 1 to 36). Primary end points were immediate technical success (vessel recanalization with residual stenosis